Vistagen Therapeutics (VTGN) Competitors $3.11 +0.03 (+0.97%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends VTGN vs. PTI, MACK, FATE, ITOS, QURE, BTMD, LXEO, ACB, KMDA, and DSGNShould you be buying Vistagen Therapeutics stock or one of its competitors? The main competitors of Vistagen Therapeutics include Proteostasis Therapeutics (PTI), Merrimack Pharmaceuticals (MACK), Fate Therapeutics (FATE), iTeos Therapeutics (ITOS), uniQure (QURE), biote (BTMD), Lexeo Therapeutics (LXEO), Aurora Cannabis (ACB), Kamada (KMDA), and Design Therapeutics (DSGN). These companies are all part of the "medical" sector. Vistagen Therapeutics vs. Proteostasis Therapeutics Merrimack Pharmaceuticals Fate Therapeutics iTeos Therapeutics uniQure biote Lexeo Therapeutics Aurora Cannabis Kamada Design Therapeutics Proteostasis Therapeutics (NASDAQ:PTI) and Vistagen Therapeutics (NASDAQ:VTGN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, profitability, dividends, community ranking, risk, analyst recommendations and media sentiment. Do institutionals and insiders believe in PTI or VTGN? 16.6% of Proteostasis Therapeutics shares are owned by institutional investors. Comparatively, 78.4% of Vistagen Therapeutics shares are owned by institutional investors. 4.8% of Proteostasis Therapeutics shares are owned by insiders. Comparatively, 1.3% of Vistagen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community favor PTI or VTGN? Proteostasis Therapeutics received 35 more outperform votes than Vistagen Therapeutics when rated by MarketBeat users. However, 72.31% of users gave Vistagen Therapeutics an outperform vote while only 59.03% of users gave Proteostasis Therapeutics an outperform vote. CompanyUnderperformOutperformProteostasis TherapeuticsOutperform Votes31759.03% Underperform Votes22040.97% Vistagen TherapeuticsOutperform Votes28272.31% Underperform Votes10827.69% Which has preferable valuation and earnings, PTI or VTGN? Vistagen Therapeutics has lower revenue, but higher earnings than Proteostasis Therapeutics. Vistagen Therapeutics is trading at a lower price-to-earnings ratio than Proteostasis Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProteostasis Therapeutics$5M0.00-$59.13M-$1.16N/AVistagen Therapeutics$971K86.65-$29.36M-$1.48-2.10 Is PTI or VTGN more profitable? Proteostasis Therapeutics has a net margin of 0.00% compared to Vistagen Therapeutics' net margin of -3,421.85%. Vistagen Therapeutics' return on equity of -35.12% beat Proteostasis Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Proteostasis TherapeuticsN/A -75.39% -55.04% Vistagen Therapeutics -3,421.85%-35.12%-32.35% Does the media favor PTI or VTGN? In the previous week, Vistagen Therapeutics had 2 more articles in the media than Proteostasis Therapeutics. MarketBeat recorded 2 mentions for Vistagen Therapeutics and 0 mentions for Proteostasis Therapeutics. Proteostasis Therapeutics' average media sentiment score of 0.00 equaled Vistagen Therapeutics'average media sentiment score. Company Overall Sentiment Proteostasis Therapeutics Neutral Vistagen Therapeutics Neutral Do analysts rate PTI or VTGN? Vistagen Therapeutics has a consensus target price of $13.50, indicating a potential upside of 334.08%. Given Vistagen Therapeutics' higher possible upside, analysts plainly believe Vistagen Therapeutics is more favorable than Proteostasis Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Proteostasis Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AVistagen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has more risk & volatility, PTI or VTGN? Proteostasis Therapeutics has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, Vistagen Therapeutics has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. SummaryVistagen Therapeutics beats Proteostasis Therapeutics on 9 of the 16 factors compared between the two stocks. Ad Porter & CompanyWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Get Vistagen Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VTGN vs. The Competition Export to ExcelMetricVistagen TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$84.14M$7.02B$5.33B$8.52BDividend YieldN/A7.92%5.07%4.13%P/E Ratio-2.1012.35128.4016.13Price / Sales86.65396.051,491.7792.21Price / CashN/A47.4339.5634.18Price / Book0.745.604.765.07Net Income-$29.36M$153.56M$118.92M$225.46M7 Day Performance3.32%-1.46%-0.39%0.07%1 Month Performance1.63%15.32%6.06%3.93%1 Year Performance1.97%43.07%38.23%32.51% Vistagen Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VTGNVistagen Therapeutics2.5445 of 5 stars$3.11+1.0%$13.50+334.1%+2.0%$84.16M$1.06M-2.1040Upcoming EarningsNews CoveragePTIProteostasis TherapeuticsN/AN/AN/AN/A$37.57M$5M-0.6244News CoverageGap UpMACKMerrimack PharmaceuticalsN/A$15.13flatN/AN/A$223.77MN/A1.09426FATEFate Therapeutics3.6267 of 5 stars$2.87+8.3%$6.90+140.4%+25.9%$326.70M$12.32M-1.68550Short Interest ↑Gap UpITOSiTeos Therapeutics2.3392 of 5 stars$8.93+2.4%$30.50+241.5%-11.1%$326.12M$12.60M-2.9890Upcoming EarningsQUREuniQure2.086 of 5 stars$6.68+2.1%$19.50+191.9%+1.7%$325.32M$15.84M-1.13500Upcoming EarningsBTMDbiote3.9631 of 5 stars$5.24+2.1%$8.39+60.1%-1.9%$325.07M$187.23M30.82194Short Interest ↓LXEOLexeo Therapeutics3.195 of 5 stars$9.83+3.5%$22.14+125.3%N/A$324.98M$650,000.00-0.6758Analyst ForecastNews CoverageACBAurora Cannabis0.7124 of 5 stars$5.95+0.3%N/A+22.3%$324.55M$278.98M-8.501,073Upcoming EarningsKMDAKamada4.4454 of 5 stars$5.45+3.2%$14.50+166.1%+32.7%$313.27M$154.57M20.19360News CoverageHigh Trading VolumeDSGNDesign Therapeutics1.3973 of 5 stars$5.53+1.7%$7.00+26.6%+157.4%$312.42MN/A-6.1440Positive News Related Companies and Tools Related Companies PTI Alternatives MACK Alternatives FATE Alternatives ITOS Alternatives QURE Alternatives BTMD Alternatives LXEO Alternatives ACB Alternatives KMDA Alternatives DSGN Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:VTGN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vistagen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vistagen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
